New Launch18 Jun 2025, 07:51 pm
Kabra Drugs Ltd: Board Approves Acquisition, FDA Permission, and Subsidiary Establishment
AI Summary
Kabra Drugs Ltd announced the outcomes of its board meeting held on 18th June 2025. The board approved and authorized Mr. N. Aravind to complete the acquisition of AMR PHARMA INDIA PRIVATE LIMITED. They also discussed a strategy for acquiring BONN SCHTERING BIO SCIENCES in Pondicherry. The company received permission from the FDA to manufacture and sell licenses for their Chennai facility. A subsidiary will be established to diversify into Artificial Intelligence and Machine Learning application for various sectors. Mr. N. Aravind was authorized to appoint and sign agreements with senior state-wise channel partners and district-wise partners all over India to sell the company's own brand of medicines.
Key Highlights
- Board approved the acquisition of AMR PHARMA INDIA PRIVATE LIMITED
- Discussion on strategy for acquiring BONN SCHTERING BIO SCIENCES
- FDA permission to manufacture and sell licenses for Chennai facility
- Establishment of a subsidiary for diversifying into various sectors
- Authorization given to appoint senior channel partners for selling own brand of medicines